Cargando…

Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations

OBJECTIVE—To further define clinical features associated with the syndrome of diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl-ester lipase (CEL) gene and to assess the effects of pancreatic enzyme substitution therapy. RESEARCH DESIGN AND METHODS—Nine patients with CEL...

Descripción completa

Detalles Bibliográficos
Autores principales: Vesterhus, Mette, Ræder, Helge, Aurlien, Harald, Gjesdal, Clara G., Bredrup, Cecilie, Holm, Pål I., Molven, Anders, Bindoff, Laurence, Berstad, Arnold, Njølstad, Pål R.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518335/
https://www.ncbi.nlm.nih.gov/pubmed/18544793
http://dx.doi.org/10.2337/dc07-2217
_version_ 1782158559430049792
author Vesterhus, Mette
Ræder, Helge
Aurlien, Harald
Gjesdal, Clara G.
Bredrup, Cecilie
Holm, Pål I.
Molven, Anders
Bindoff, Laurence
Berstad, Arnold
Njølstad, Pål R.
author_facet Vesterhus, Mette
Ræder, Helge
Aurlien, Harald
Gjesdal, Clara G.
Bredrup, Cecilie
Holm, Pål I.
Molven, Anders
Bindoff, Laurence
Berstad, Arnold
Njølstad, Pål R.
author_sort Vesterhus, Mette
collection PubMed
description OBJECTIVE—To further define clinical features associated with the syndrome of diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl-ester lipase (CEL) gene and to assess the effects of pancreatic enzyme substitution therapy. RESEARCH DESIGN AND METHODS—Nine patients with CEL gene mutation, exocrine deficiency, and diabetes were treated and followed for 30 months. RESULTS—Treatment improved symptoms in seven of nine patients. Exocrine and endocrine function assessed by fecal elastase and A1C were not affected, although fecal lipid excretion was reduced. Vitamin E was low in all patients but increased with treatment (P < 0.001 at 30 months) and improved in five subjects. A predominantly demyelinating neuropathy was seen in a majority of patients, and carpal tunnel syndrome was common. CONCLUSIONS—Pancreatic enzyme substitution alleviated symptoms and malabsorption and normalized vitamin E levels. Glycemic control was not significantly affected. The CEL syndrome seems associated with a demyelinating neuropathology.
format Text
id pubmed-2518335
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-25183352009-09-01 Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations Vesterhus, Mette Ræder, Helge Aurlien, Harald Gjesdal, Clara G. Bredrup, Cecilie Holm, Pål I. Molven, Anders Bindoff, Laurence Berstad, Arnold Njølstad, Pål R. Diabetes Care Clinical Care/Education/Nutrition/Psychosocial Research OBJECTIVE—To further define clinical features associated with the syndrome of diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl-ester lipase (CEL) gene and to assess the effects of pancreatic enzyme substitution therapy. RESEARCH DESIGN AND METHODS—Nine patients with CEL gene mutation, exocrine deficiency, and diabetes were treated and followed for 30 months. RESULTS—Treatment improved symptoms in seven of nine patients. Exocrine and endocrine function assessed by fecal elastase and A1C were not affected, although fecal lipid excretion was reduced. Vitamin E was low in all patients but increased with treatment (P < 0.001 at 30 months) and improved in five subjects. A predominantly demyelinating neuropathy was seen in a majority of patients, and carpal tunnel syndrome was common. CONCLUSIONS—Pancreatic enzyme substitution alleviated symptoms and malabsorption and normalized vitamin E levels. Glycemic control was not significantly affected. The CEL syndrome seems associated with a demyelinating neuropathology. American Diabetes Association 2008-09 /pmc/articles/PMC2518335/ /pubmed/18544793 http://dx.doi.org/10.2337/dc07-2217 Text en Copyright © 2008, DIABETES CARE Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Clinical Care/Education/Nutrition/Psychosocial Research
Vesterhus, Mette
Ræder, Helge
Aurlien, Harald
Gjesdal, Clara G.
Bredrup, Cecilie
Holm, Pål I.
Molven, Anders
Bindoff, Laurence
Berstad, Arnold
Njølstad, Pål R.
Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations
title Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations
title_full Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations
title_fullStr Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations
title_full_unstemmed Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations
title_short Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations
title_sort neurological features and enzyme therapy in patients with endocrine and exocrine pancreas dysfunction due to cel mutations
topic Clinical Care/Education/Nutrition/Psychosocial Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518335/
https://www.ncbi.nlm.nih.gov/pubmed/18544793
http://dx.doi.org/10.2337/dc07-2217
work_keys_str_mv AT vesterhusmette neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations
AT ræderhelge neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations
AT aurlienharald neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations
AT gjesdalclarag neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations
AT bredrupcecilie neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations
AT holmpali neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations
AT molvenanders neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations
AT bindofflaurence neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations
AT berstadarnold neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations
AT njølstadpalr neurologicalfeaturesandenzymetherapyinpatientswithendocrineandexocrinepancreasdysfunctionduetocelmutations